THISX — T. Rowe Price Health Sciences Fund, Inc.
Data updated: 2026-08-27
THISX — T. Rowe Price Health Sciences Fund, Inc. United States Large Cap Blend / Core Health Care Equity. Holdings, fees, performance and SEC filings.
THISX Fund Overview
THISX — T. Rowe Price Health Sciences Fund, Inc. is a US mutual fund managed by T. Rowe Price Health Sciences Fund, Inc., categorised as United States Large Cap Blend / Core Health Care Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US mutual fund
- Manager: T. Rowe Price Health Sciences Fund, Inc.
- Category: United States Large Cap Blend / Core Health Care Equity
- Assets under management: $11.95B
- 1-year return: 30.2%
- Ticker: THISX
- SEC CIK: 0001002624
- SEC series ID: S000002088
- Share class ID: C000169937
THISX Holdings
Top 10 holdings of T. Rowe Price Health Sciences Fund, Inc. by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| Eli Lilly & Co. | 14.28% |
| Johnson & Johnson | 6.63% |
| Unitedhealth Group, Inc. | 5.99% |
| Abbvie, Inc. | 5.10% |
| Merck & Co. Inc. | 4.01% |
| Gilead Sciences, Inc. | 2.82% |
| Thermo Fisher Scientific, Inc. | 2.52% |
| Vertex Pharmaceuticals, Inc. | 2.28% |
| Bristol-Myers Squibb Co. | 2.11% |
| Abbott Laboratories | 1.89% |
THISX Portfolio Allocation
Asset-class allocation of T. Rowe Price Health Sciences Fund, Inc. by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 99.4% |
| Cash & Equivalents | 0.6% |
| Fixed Income | 0.1% |
THISX Performance
Total returns for THISX (as of 2026-09-01), from SEC filings.
| Period | Total return |
|---|---|
| YTD | 7.3% |
| 1 year | 30.2% |
| 3 years (annualised) | 9.6% |
| 5 years (annualised) | 3.9% |
THISX Risk Information
Risk metrics for THISX, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 16.0%
THISX Costs and Fees
THISX costs about $68 per $10,000 invested per year in fund expenses.
- Net expense ratio: 0.68%
- Gross expense ratio: 0.68%
- Portfolio turnover: 62%
- Brokerage commissions: 3.19 bps of average net assets (SEC N-CEN)
THISX Cashflows
Over the 12 months to 2026-06, T. Rowe Price Health Sciences Fund, Inc. had net outflows of $1.02B, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2026-06 | −$153.49M |
| 2026-05 | −$164.06M |
| 2026-04 | −$146.67M |
| 2026-03 | −$152.96M |
| 2026-02 | −$146.76M |
| 2026-01 | −$154.04M |
THISX Debt Constituents
Largest debt holdings of T. Rowe Price Health Sciences Fund, Inc. by percentage of net assets, from the latest SEC N-PORT filing.
| Debt holding | % of net assets |
|---|---|
| Immunocore Holdings Cb 2.50% 2/30 | 0.11% |
| Delfi Diagnostics CVT Prom Note PP | 0.01% |
| Kartos Therapeutics CVT Prom Note 03/27 PP | 0.01% |
| Reflexion Med CVT Note issued 081325 PP | 0.01% |
| Reflexion Med CVT Note issued 072525 PP | 0.01% |
| Reflexion Med CVT Note issued 082725 PP | 0.01% |
| Kartos Therapeutics CVT Note 05/27 PP | 0.00% |
THISX Prospectus and SEC Filings
Official T. Rowe Price Health Sciences Fund, Inc. filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
- Prospectus (485BPOS) — filed 2026-02-25
- Prospectus (485BPOS) — filed 2025-02-25
- Prospectus (485BPOS) — filed 2024-04-25
- Portfolio holdings (N-PORT) — filed 2026-08-27
- Portfolio holdings (N-PORT) — filed 2026-05-28
- Portfolio holdings (N-PORT) — filed 2026-02-26
- Annual census (N-CEN) — filed 2026-03-13
- Annual census (N-CEN) — filed 2025-03-14
Related Funds
Other United States Large Cap Blend / Core Health Care Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.